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In 2016, a very impressive report was published describing that osteosarcoma (OS) is the
earliest human cancer in the fossil record, dating back 1.7 million years to the Homo ergaster
era [1]. This demonstrated that OS is the oldest recognized malignant neoplasm with concrete
(no pun intended) evidence. In general, OS is the most common malignant bone tumor and
mostly affects children, adolescents, and young adults. OS shows significant genetic instability,
resulting in a very complex biology with multifaceted cellular and molecular mechanisms and
behaviors. This is the main reason why treatment options are still limited and the prognosis
has remained unchanged for several decades, despite significant improvements in the 1980s
through advancements in systemic chemotherapy and definitive surgery [2]. The prognosis for
patients with relapsed and/or metastatic disease is still quite poor.
The concept of “toward precision medicine” was proposed in 2011 to bring about a new
treatment paradigm in which clinicians, researchers, patients, policymakers, the pharmaceuti-
cal industry, and health care systems work together to improve human health at all levels—
disease prevention, diagnosis, and treatment—through the development of more precise,
individualized care [3]. Because of the chaotic genetic background of OS and its lack of
treatment options, which still mainly involve radical surgery and non-specific combination
chemotherapy, the concept of precision medicine could be the most highly desired platform for
patients with OS. This chaos of OS biology probably started 1.7 million or even more years ago.
The complicated genetic background of OS is characterized by an extremely heterogeneous
genetic alteration spectrum. The most historical and thoroughly described genetic alterations
in patients with OS are aberrations of the tumor suppressors p53 and Rb, which cause hered-
itary dispositions to Li-Fraumeni syndrome and retinoblastoma, respectively [4]. Because both
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the p53 and Rb pathways are involved in cell cycle regulation, other cell cycle regulators such
as p16INK4a/p19ARF and MDM2 have also been investigated [5]. These tumor suppressors
and their associated pathways are still a staple of research for potential therapeutic targets in
patients with OS. However, treatments targeting these pathways thus far have failed to show
substantial impact.
Recent advances in next-generation sequencing, including whole-genome sequencing, whole-
exome sequencing, and RNA sequencing, have revealed several possible candidate pathways
involved in OS development. In a study performed at St. Jude Children’s Research Hospital,
Chen et al. [6] reported that next-generation sequencing of pediatric OS specimens revealed
recurrent somatic alterations: structural variations and/or single-nucleotide variation in the
ATRX and DLG2 genes. Among those, the PI3K/mTOR signaling pathways, including the
PTEN, PI3K/Akt, and IGF1/mTOR pathways, have emerged as possible therapeutic targets in
patients with OS [7]. A genome-wide siRNA screening with a screen of therapeutically rele-
vant small molecules have identified the dual inhibition of the PI3K-mTOR pathway as a
sensitive druggable target in OS [8]. A Sleeping Beauty transposon-based forward genetic
screen also highlighted that OS driver genes are enriched in the ERBB, PI3K–AKT–mTOR,
MAPK, PTEN, and NF2 signaling pathways [9]. Several specific inhibitors of the PI3K–AKT–
mTOR pathway have been developed, and their efficacy against OS has been investigated;
some of these inhibitors have already been applied in clinical trials [10].
High-throughput screening technologies, including those that involve microRNA (miRNA),
have also had a huge impact on the cancer research field. miRNAs are small non-coding RNAs
that play critical roles in the regulation of gene expression at the post-transcriptional level and
in the control of cellular processes such as proliferation, differentiation, initiation, and progres-
sion of various diseases including cancer. More than 2500 miRNAs have been identified, and
many of them function as oncogenes or tumor suppressors that regulate gene and protein
expression. Some miRNAs like miR-34a and miR-21, target genes involved in OS development
such as the p53 and Rb genes as well as the PI3K/Akt/mTOR, IGF-R1, and MAPK pathways.
Some miRNAs could be proposed as potential biomarkers of disease progression and metas-
tasis, and may serve as therapeutic targets for OS [11].
For precise, personalized therapeutic approaches, especially in the prediction of the response
to chemotherapy, the establishment of predictive biomarkers is a long-standing goal in OS
research. The “-omics” approach at the genome, transcriptome, and proteome levels has been
applied to identify the predictive biomarkers of OS, and several potential candidates have been
identified [12]. Hagleitner et al. [13] recently identified the association between five-year
progression-free survival and five genetic variants [the Fas Ligand (FasL), MutS homologue 2
(MSH2), ATP-binding cassette sub-family C (ABCC5), caspase 3 (CASP3), and cytochrome
P450 3A4 (CYP3A4)] using a linkage disequilibrium-based tag single-nucleotide polymor-
phism strategy. They found that patients with fewer risk alleles showed a more favorable
prognosis. They concluded that these pharmacogenetic risk factors might be useful to predict
treatment outcomes and to stratify patients, thus allowing for more personalized treatment
[13]. Recent studies have also uncovered the important roles of the tumor microenvironment,
including tumor stromal cells and extracellular matrices, in the development of OS. Mesenchymal
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stromal/stem cells (MSCs) or MSC-derived lineage-specific progenitors have long been considered
as the cells of origin for certain types of sarcomas, including OS [14]. Additionally, OS develop-
ment is closely linked to certain oncogenic lesions, such as p53 and Rb deficiency in MSCs, and to
bone microenvironment signals such as calcified substrates and bone morphogenetic protein-2
[15]. MSCs are not only the putative cells of origin for sarcomas, but are also thought to be the
source of cancer-associated fibroblasts, one of the key players in the tumor microenvironment for
cancer progression [16]. Several studies have proposed that the mechanism of the interaction
between MSCs and tumor cells could be a potential therapeutic target against OS. A recent study
by an Italian group demonstrated that MSCs in the tumor stroma driven by oxidative stress
induced by OS cells could be potential modulators of the metabolism of OS cells that underwent
mitochondrial biogenesis to increase the mitochondrial activity [17]. The authors suggested that
this mutual metabolic reprogramming of OS cells and their stroma could also represent a possible
target for OS therapies.
Despite remarkable progress in these fields, the results of studies of specific inhibitors of
possible targetable pathways and specific biomarkers have not yet been applicable to the
clinical setting. However, continued progress in -omics technology, next-generation sequenc-
ing, and high-throughput screening will provide new insights into the pathogenesis of OS and
will help to identify novel biomarkers that will contribute to improved therapeutic strategies,
prognoses, and quality of life.
The role of immunotherapy has been investigated in both the preclinical and clinical settings in
OS. Immunotherapeutic techniques include the use of nonspecific immunomodulators such as
muramyl tripeptide phosphatidylethanolamine [18], interferons [19], interleukin-2 [20], adop-
tive T-cell immunotherapy, vaccines, immunologic checkpoint blockades such as CTLA-4/PD-1
blockade, and oncolytic viral therapy. It is very important to continue the development of
immunotherapeutic strategies, especially for patients with metastatic disease in whom effec-
tive systemic therapy is not a treatment option.
Advances in imaging modalities, surgical procedures, and neoadjuvant chemotherapy have
allowed more limb salvaged and less amputation to be performed. Megaprosthetic replace-
ment has become more popular for limb salvage than any other technique, including the use of
allografts and vascularized autografts. However, when preoperative chemotherapy is effective
and tumor locates far enough from the joint surface, joint preservation rather than megaprosthetic
replacement has been utilized. Joint preservation can be achieved using so-called biological
reconstruction methods including allografts, vascularized autografts, and processed autologous
bone grafts. Processed autologous bone grafts have been developed to utilize the patient’s own
diseased bone sterilized by irradiation, pasteurization, and liquid nitrogen freezing. However,
precise evaluation and surgical planning are required for joint-preserving reconstruction.
Recent advances in three-dimensional (3D) imaging and printing techniques have already had
a significant impact on orthopedic surgery. Especially for musculoskeletal tumor resection and
reconstruction, 3D visualization of computed tomographic and magnetic resonance images
has become an effective supportive tool for surgical planning and determination of surgical
margins. In addition, a precise personalized anatomical model of the surgical site by 3D
printing can be created for each patient, and personalized guiding templates fabricated by 3D
Introductory Chapter: From Chaos to Cosmos – Toward Precision Medicine in Osteosarcoma
http://dx.doi.org/10.5772/67265
5
printing with computer-assisted designs have been utilized for many orthopedic surgeries,
including resection of OS [21]. The jaw, including the mandible and maxilla, is a region where
OS is occasionally involved, representing 7% of all cases of OS and 1% of all head and neck
malignancies [22]. Although definitive surgery is still the mainstay of jaw OS treatment,
precise tumor resection is sometimes difficult to achieve because of the anatomical complexity
of the maxillofacial region. In this clinical setting of OS of the jaw, as well as in joint-preserving
surgery, 3D imaging and printing techniques will be of great help for precise surgical treatment
of OS.
A multi-disciplinary approach is essential for the management of OS. Among many clinical
symptoms of OS, pain is the most prominent symptom and sometimes requires multimodal
treatments. Recent studies have demonstrated that molecular pathways such as the MAPK
and PI3K pathways, which are closely involved in OS development as described earlier, play
critical roles in regulating the cell signaling of transient receptor potential vannilloid subfamily
member 1 (TRPV1), a nocioceptive receptor among peripheral nerve fibers that is closely
linked in cancer pain [23, 24]. Therefore, these pathways could be possible targets for both
cancer-induced pain as well as OS development.
Comparative oncology approaches through translational research involving rodent,
canine, and human, models could provide new insights for OS treatment strategies. Genet-
ically engineered mouse models of OS have been created, such as those exhibiting Cre/
LoxP–mediated deletion of p53 and/or Rb [25]. A novel model of OS developed using the
Sleeping Beauty transposon mutagenesis system was recently established [9]. These mouse
models will be useful to identify new candidate driver genes of OS development. While the
incidence of OS in humans is roughly 25 per 10 million cases per year in the US, it is about
15 times more common in dogs. The natural history of OS and the genome-wide expres-
sion profiles are very similar between humans and canines OS [26]. Comparative studies
using a multi-species approach will be indispensable for OS research and will allow us to
identify true driver genes and pathways that will provide novel therapeutic targets and
new therapeutic strategies encompassing the fields of chemotherapy, immunotherapy, and
surgery.
Precision medicine in the management of OS should be a multidisciplinary effort involving
the collaboration of both medical and non-medical professions. Involved individuals
should include family members, friends, teachers, and colleagues in the patients’ schools
and work places. We hope that the findings provided herein will be helpful for all individ-
uals dealing with OS, including physicians, researchers, and patients and their family
members.
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